IP Library Granted Patent US 10,272,051
Granted Patent B2
US 10,272,051 · App. 16/106,524 · Granted Apr 30, 2019

Method to treat atopic dermatitis

Inventors: Lekhram Changoer (Ridderkerk, NL); George Anastassov (New York, NY)
Assignee: Axim Biotechnologies, Inc.
A61K31/05A61K9/0014A61K9/0019A61K9/0058A61K9/06A61K31/352A61K47/44A61P17/00A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,051
App. No.
16/106,524
Granted
Apr 30, 2019
Kind
B2
Abstract

A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.

Claims (18)

1. A method to treat atopic dermatitis, comprising:

administering a topical composition containing cannabinoids onto skin areas of a subject in need thereof,

wherein the cannabinoids are cannabidiol and cannabigerol at a total weight percent of 3% to 20% of the composition.

2. The method of claim 1 , wherein the cannabigerol is present at a twice to three times the weight of cannabidiol.

3. The method of claim 1 , wherein the cannabinoids in the composition are in powder form prior to incorporation into the composition.

4. The method of claim 1 , wherein the cannabinoids in the composition are in crystalline form prior to incorporation into the composition.

5. The method of claim 1 , wherein the cannabinoids in the composition are microencapsulated.

6. The method of claim 1 , wherein the cannabinoids in the composition are nanoencapsulated with particle sizes of 20 to 40 nanometers.

7. The method of claim 1 , wherein the composition further comprises a hyaluronic acid derivative.

8. The method of claim 7 , wherein the hyaluronic acid derivative is sodium oleyl hyaluronate.

9. The method of claim 8 , wherein the composition further comprises at least one of omega-3 or omega-6 fatty acids.

10. The method of claim 9 , wherein the composition further comprises cacao butter.

11. The method of claim 1 , wherein the composition is in a hydro gel form, a liquid form, a spray form, or a powder form.

12. The method of claim 1 , wherein the topical composition is applied twice a day for six weeks.

13. The method of claim 1 , further comprising oral administration of chewing gums containing at least one cannabinoid to the subject.

14. The method of claim 13 , wherein the at least one cannabinoid in the chewing gums is cannabidiol and the chewing gums contains 10 milligrams of cannabidiol in each piece.

15. The method of claim 13 , wherein the chewing gums contain 0.01% to 10% of cannabinoids by total weight of the chewing gum composition.

16. The method of claim 13 , wherein the chewing gums are administered 3 times per day for six weeks.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: AXIM BIOTECHNOLOGIES, INC.
To: APIRX PHARMACEUTICAL USA, LLC
Reel/Frame 052752/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: CHANGOER, LEKHRAM; ANASTASSOV, GEORGE
To: AXIM BIOTECHNOLOGIES, INC.
Reel/Frame 046819/0785 →
Continuity (2)
Provisional Application 62550880 · Aug 28, 2017
Related Publication 20190060251A1 · Feb 28, 2019
Cited By (1)
US 12,440,454